ARWR: Double Bottom detected on 27 Oct 2026

ARWR is forming a double_bottom pattern at $58.98, positioned 59.92% above its 52-week low and 38.23% below the 52-week high. The structure score of 13.12/15 indicates well-defined lows around key support at $55.83. Volume score of 12.0/12 shows solid confirmation, though recent volume is 53% of the 20-day average, suggesting accumulation rather than climactic breakout. Breakout score of 13.0/13 reflects clean price action above intermediate resistance. The 65.23% win probability and 64.12 overall score indicate a moderate-to-solid setup. RSI at 36.74 is oversold, providing room for reversal. The secondary bullish pennant (36.0 pattern quality, 28 days in pattern) reinforces the consolidation structure.

On October 14, 2026, Arrowhead announced interim Phase 1/2a results for ARO-MAPT showing 73% mean cerebrospinal fluid total tau reduction on Day 105, with the company's TRiM platform achieving clinical validation for blood-brain barrier delivery. On October 15, Piper Sandler initiated a Buy rating and UBS initiated coverage with a Buy on October 14. Goldman Sachs maintained a Neutral rating with a $74 target. The company acquired an FDA priority review voucher for an upcoming plozasiran sNDA submission before end of 2026, which accelerates FDA review to 6 months versus 10 months. In February, Arrowhead received $200 million upfront from Novartis with up to $2 billion in development and regulatory milestone payments. The recent tau data and upgraded analyst coverage appear to be driving renewed interest, offsetting three months of downside.

The double_bottom setup targets $61.95 (conservative target), representing 5.0% upside from current price. A successful breakout requires volume confirmation above recent resistance levels and sustained closes above $59.50. The key invalidation level sits at the double_bottom support at $55.83—a close below this price would negate the pattern setup. Historical double_bottom patterns at 65% win probability suggest a 2:1 risk-reward favorable bias if the pattern holds. The measured move from the double_bottom troughs to resistance creates defined risk parameters. MACD histogram at 0.5404 is mildly positive, supporting early momentum building.

Valuation models suggest ARWR trading 48% undervalued at fair value of $110.18 versus recent $57.23 close, but this represents significant execution risk on pipeline commercialization. Current volume at 53% of 20-day average indicates weak participation and potential liquidity constraints on breakout attempts. Goldman Sachs' Neutral rating with $74 target creates near-term resistance headwind despite recent positive data. The stock has declined 31.24% over three months and 10.53% in the past month—momentum is severely damaged despite fundamental catalyst. Beta of 0.66 provides some downside protection, but biotechnology volatility (3.85% ATR) remains elevated. ARO-MAPT data requires 2027 updates before meaningful value realization, leaving near-term price action vulnerable to sector rotation or macro healthcare headwinds.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.